Patent Expiry Crisis and Major Cost Reduction

Takeda Pharmaceutical (Takeda, TAK) is facing stagnation in growth due to the patent expiry of its flagship ADHD treatment Vyvanse (lisdexamfetamine) and the entry of generics, which are expected to reduce sales by 1.7% in the 2025 fiscal year. In response, Takeda has launched a major organizational downsizing initiative, aiming to cut annual costs by 200 billion yen (approximately 1.26 billion USD) by the 2028 fiscal year. As part of this restructuring, approximately 1.5 trillion yen (about 925.8 million USD) in one-time costs are expected to be recognized in the 2026 fiscal year, including a large-scale reduction of around 4,500 employees. This move is not merely about budget cuts but a strategic decision to reduce the weight of its stagnant legacy portfolio and reallocate resources toward high-value specialty pharmaceutical pipelines.

Oveporexton: A Game Changer in Narcolepsy Treatment

Oveporexton (TAK-861), positioned as a core pillar of Takeda's next-generation growth strategy 'Horizon One,' is an orexin receptor 2 (OX2R) agonist targeting Narcolepsy Type 1 (NT1). Unlike existing treatments that only alleviate daytime sleepiness or cataplexy symptoms, this drug is a first-in-class candidate that directly compensates for the root cause of the disease—loss of orexin neurons. It demonstrated excellent efficacy and safety in Phase 3 trials, earning Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and currently undergoing Priority Review. It is expected to completely transform the global narcolepsy market, which was valued at approximately 2.5 billion USD in 2024, by offering a fundamental treatment option for NT1 patients.

Rusfertide Targets the Hematologic Malignancy Market

Rusfertide (PTG-300), a hepcidin mimetic peptide developed for the treatment of Polycythemia Vera (PV), a rare blood disorder, was acquired by Takeda in 2024 from Protagonist Therapeutics for an upfront payment of 300 million USD. Traditional standard treatments such as hydroxyurea or frequent phlebotomy have significantly reduced patients' quality of life, but Rusfertide lowers blood transfusion dependency by directly regulating iron metabolism to suppress red blood cell production. Having achieved positive topline results in the Phase 3 VERIFY trial, the drug is currently under Priority Review by the U.S. FDA and is expected to launch in the U.S. market in the second half of 2026. Recently, Protagonist exited the U.S. profit-sharing agreement, allowing Takeda to fully secure exclusive commercialization rights in the U.S., which is expected to maximize revenue contribution.

Zasocitinib: A Potent TYK2 Inhibitor Challenging the Psoriasis Market

Zasocitinib (TAK-279), Takeda's final key pipeline, is a highly selective oral TYK2 (Tyrosine kinase 2) inhibitor acquired in 2022 from Nimbus Therapeutics for an upfront payment of 4 billion USD. In clinical trials for moderate to severe plaque psoriasis, Zasocitinib demonstrated superior skin improvement compared to existing approved competitors such as Bristol Myers Squibb's Sotyktu and Amgen's Otezla. The drug offers the advantage of biological-level efficacy without the high-quality side effects commonly associated with JAK inhibitors, such as cardiovascular and thrombotic risks. With the global psoriasis treatment market valued at approximately 23.3 billion USD in 2025, Zasocitinib is expected to achieve rapid market penetration as a convenient oral therapy. Takeda plans to complete regulatory filing by the end of this year.

AI Partnerships to Optimize R&D Pipeline Efficiency

Takeda is significantly strengthening external collaborations with AI-based platform companies to increase the success rate of drug development and reduce costs. In 2026, it entered multi-year partnerships with Iambic Therapeutics and Insilico Medicine, applying AI platforms such as Pharma.AI to drug discovery. This strategy aims to reinforce late-stage clinical pipelines by rapidly screening blockbuster drug candidates in early R&D stages, while simultaneously controlling internal costs through restructuring. Ultimately, it is the successful commercialization speed and market penetration of these new drugs, along with R&D efficiency improvements through technological innovation and portfolio diversification, that will determine Takeda's ability to overcome revenue cliffs caused by legacy product patent expiries and enter a sustainable growth trajectory.